TY - JOUR
AU - Lund, Sophie
AU - Gong, Chun
AU - Yu, Xin
AU - Staudt, Louis M
AU - Hodson, Daniel J
AU - Scheich, Sebastian
TI - Strategies for CRISPR-based knock-ins in primary human B cells and lymphoma cell lines.
JO - Frontiers in immunology
VL - 16
SN - 1664-3224
CY - Lausanne
PB - Frontiers Media
M1 - DKFZ-2025-01131
SP - 1589729
PY - 2025
AB - Since its advent about ten years ago, the CRISPR-Cas9 system has been frequently used in biomedical applications. It has advanced various fields, and CRISPR-Cas9-based therapeutics have shown promising results in the treatment of specific hematological diseases. Furthermore, CRISPR gene editing technologies have revolutionized cancer research by enabling a broad range of genetic perturbations, including genetic knockouts and precise single nucleotide changes. This perspective focuses on the state-of-the-art methodology of CRISPR knock-ins to engineer immune cells. Since this technique relies on homology-directed repair (HDR) of double-strand breaks (DSBs) induced by the Cas9 enzyme, it can be used to introduce specific mutations into the target genome. Therefore, this methodology offers a valuable opportunity to functionally study specific mutations and to uncover their impacts not only on overall cell functions but also on the mechanisms behind cancer-related alterations in common signaling pathways. This article highlights CRISPR knock-in strategies, protocols, and applications in cancer and immune research, with a focus on diffuse large B cell lymphoma.
KW - Humans
KW - CRISPR-Cas Systems
KW - Gene Knock-In Techniques: methods
KW - Gene Editing: methods
KW - B-Lymphocytes: metabolism
KW - B-Lymphocytes: immunology
KW - Cell Line, Tumor
KW - Lymphoma, Large B-Cell, Diffuse: genetics
KW - DLBCL (Other)
KW - NF-kappa B (NF-KB) (Other)
KW - gene editing (CRISPR/Cas9) (Other)
KW - knock-in (Other)
KW - lymphoma (Other)
LB - PUB:(DE-HGF)16
C6 - pmid:40453079
C2 - pmc:PMC12122508
DO - DOI:10.3389/fimmu.2025.1589729
UR - https://inrepo02.dkfz.de/record/301747
ER -